The goal ofthe University of lowa / Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Developmental Research Program is to support innovative, scientifically sound projects that investigate a question pertaining to translational lymphoma research. This program was highly successful with past and current support over the past 4 years going to 13 developmental research projects. Three of these projects have received external, peer-reviewed NCI funding or a fundable priority score, 3 received a second year of funding, and 3 provided data that was instrumental for the major research projects selected for this renewal. The Developmental Research Program will provide up to $50,000 for one year ($25,000 from UI/MC SPORE funds and a matching $25,000 from institutional resources) to each of four projects each year with the possibility of a second year of support based on progress. It is anticipated that support of developmental research projects will continue to result in the generation of new hypotheses that will be tested in full UI/MC SPORE-sponsored projects or through peer reviewed external grant support. The long-term goal of the UI/MC SPORE program is to translate the findings generated by developmental projects into a reduction in the incidence and mortality rates of lymphoma. More specifically, the objectives ef the Developmental Research Program are to: (1) encourage innovative translationally-relevant laboratory, population and clinical studies in lymphoma and chronic lymphocytic leukemia;(2) foster extensive collaboration between basic science, population science and clinical disciplines in translational research in lymphoma;and, (3) generate new hypotheses to be tested in large-scale research projects or clinical trials that may lead to significant reduction of lymphoma incidence and mortality. Brief outlines of four developmental research projects from investigators at the University of lowa and the Mayo Clinic are included to demonstrate the depth and breadth of ongoing research that can be applied to the translational lymphoma research at these institutions and could be eligible for UI/MC SPORE Developmental Program support.

Public Health Relevance

The UI/MC SPORE in Lymphoma Developmental Research Program (DRP) was established to fund early phase research that takes maximum advantage of UI/MC SPORE resources to generate feasibility data for projects that have the highest translational potential. The DRP encourages proposals from investigators in related disciplines se as to rapidly translate new treatment concepts to patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097274-13
Application #
8689953
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Hill, Brian T; Nastoupil, Loretta; Winter, Allison M et al. (2018) Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol :
McPhail, Ellen D; Maurer, Matthew J; Macon, William R et al. (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103:1899-1907
J Pelletier, Daniel; O'Donnell, Michael; Stone, Mary Seabury et al. (2018) Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 45:453-457
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Thanarajasingam, Gita; Minasian, Lori M; Baron, Frederic et al. (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 5:e563-e598
Ravi, Praful; Kumar, Shaji K; Cerhan, James R et al. (2018) Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 8:26
McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182
Pophali, Priyanka A; Ip, Andrew; Larson, Melissa C et al. (2018) The association of physical activity before and after lymphoma diagnosis with survival outcomes. Am J Hematol 93:1543-1550
Shenoy, Niraj; Creagan, Edward; Witzig, Thomas et al. (2018) Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. Cancer Cell 34:700-706
Maurer, M J; Habermann, T M; Shi, Q et al. (2018) Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol 29:1822-1827

Showing the most recent 10 out of 387 publications